Prevention of meningococcal serogroup C disease by NeisVac-C™

Expert Review of Vaccines

Volumn 8, Issue 3, 2009, Pages 265-279

  Borrow, Ray ^a   Findlow, Jamie ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Efficacy; Herd immunity; Immunogenicity; Meningococcal serogroup C conjugate vaccine; NeisVac C ; Reactogenicity

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; ORAL POLIOMYELITIS VACCINE; PEDIACEL; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID; TRIVAX AD; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE TETANUS TOXIN CONJUGATE; HAEMOPHILUS INFLUENZA TYPE B POLYSACCHARIDE VACCINE-TETANUS TOXIN CONJUGATE; HAEMOPHILUS VACCINE; VACCINE;

ABDOMINAL PAIN; ANAPHYLAXIS; CONVULSION; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEVER; GUILLAIN BARRE SYNDROME; HAEMOPHILUS INFLUENZAE TYPE B; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MENINGOCOCCOSIS; NAUSEA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PURPURA; REVIEW; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; VACCINATION; VOMITING; ADOLESCENT; ADULT; BLOOD; CHILD; EPIDEMIC MENINGITIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; TETANUS TOXOID; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 63849194065     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.3.265     Document Type: Review

References (61)

1. Rosenstein NE, Perkins BA, Stephens DS et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180, 1894-1901 (1999).
2. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med. 344, 1378-1388 (2001).
3. Branham SE. Serological relationships among meningococci. Bacteriol. Rev. 17, 175-188 (1953).
4. Vedros NA. Development of meningococcal serogroups. In: Evolution of Meningococcal Disease. Vedros NA (Ed.). CRC Press Inc., FL, USA 33-37 (1987).
5. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Vaccines (5th Edition) Plotkin SA, Offit P, Orenstein WA (Eds). WB Saunders Company, PA, USA 399-434 (2008).
6. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 188, 481-485 (2003).
7. Bilukha OO, Rosenstein N. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54, 1-21 (2005).
8. Schmitt HJ, Maechler G, Habermehl P et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae - Neisseria meningitidis serogroup C conjugate vaccine. Clin. Vaccine Immunol. 14, 426-434 (2007).
9. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect. Dis. 5, 21-30 (2005).
10. Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines 5(6), 851-857 (2006).
11. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev. Vaccines 5(2), 269-275 (2006).
12. Michon F, Huang CH, Farley EK, Hronowski L, Di J, Fusco PC. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev. Biol. (Basel) 103, 151-160 (2000).
13. Lee S-M, Petermann R, Porte Q, Berezuk G, Crowe B, Shirtz J. Long-term thermal stability of group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine. Hum. Vaccin. 3, 27-32 (2007).
14. Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharide- protein conjugate vaccines. Arch. Dis. Child. 92, 909-915 (2007).
15. Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ 333, 571 (2006).
16. Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine - United States, June-August 2005. MMWR Morb. Mortal. Wkly Rep. 55, 1016-1017 (2006).
17. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med. 129, 1307-1326 (1969).
18. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: II. Development of natural immunity. J. Exp. Med. 129, 1327-1348 (1969).
19. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23, 2222-2227 (2005).
20. Griffis JM, Goroff DK. IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J. Immunol. 130, 2882-2885 (1983).
21. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40, 257-264 (1983).
22. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: a re-evaluation of correlates of protection. Infect. Immun. 69, 1568-1573 (2001).
23. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clin. Diag. Lab. Immunol. 10, 780-786 (2003). •• Validates the serologic correlate of protection for serogroup C.
24. Richmond P, Borrow R, Findlow J et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect. Immun. 69, 2378-2382 (2001).
25. Borrow R, Goldblatt D, Finn A et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in U.K. infants. Infect. Immun. 71, 5549-5555 (2003).
26. Richmond PC, Miller E, Borrow R et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179, 1569-1572 (1999).
27. Kitchin NR, Southern J, Morris R et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch. Dis. Child. 92, 11-16 (2007).
28. English M, MacLennan JM, Bowen-Morris JM et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19, 1232-1238 (2000).
29. Southern J, Crowley-Luke A, Borrow R, Andrews N, Miller E. Immunogenicity of meningococcal C conjugate vaccine conjugated to tetanus toxoid after each dose, given as a three-dose primary vaccination course in infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24, 215-219 (2006).
30. 5/Hib/IPV vaccine in healthy UK infants. Clin. Vaccine Immunol. 16(2), 194-199 (2008).
31. Kollaritsch H, Behre U. A randomized, open-label trial of Neisvac-C vaccine to evaluate immunological interference with hepatitis B, inactivated polio and acellular pertussis vaccines in healthy infants. Data on file: Baxter Bioscience (2002).
32. Tejedor JC, Moro M, Ruiz-Contreras J et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr. Infect. Dis. J. 25, 713-720 (2006).
33. Vesikari T, Karvonen A, Korhonen T et al. Immunogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid vaccine (Hib-MenC-TT) following a 3, 5, 11 month schedule. Program and Abstracts of the 26th Annual meeting of the European society for Paediatric infectious Diseases - ESPID. Graz, Austria (2008) (Abstract 694).
34. Tejedor JC, Moro M, Merino JM et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatr. Infect. Dis. J. 27, 579-588 (2008).
35. Richmond P, Borrow R, Goldblatt D et al. Ability of three different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers. J. Infect. Dis. 183, 160-163 (2001).
36. Burrage M, Robinson A, Borrow R et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect. Immun. 70, 4946-4954 (2002).
37. Richmond P, Goldblatt D, Fusco PC et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18, 641-646 (1999).
38. Southern J, Deane S, Ashton L et al. Effect of prior polysaccharide vaccination on magnitude, duration and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin. Diag. Lab. Immunol. 11, 1100-1104 (2004).
39. Borrow R, Southern J, Andrews N et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls. Vaccine 19, 3043-3050 (2001).
40. Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTaP-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev. Vaccines 7(1), 97-115 (2008).
41. Southern J, Gelb D, Andrews N et al. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, a month prior to or after, tetanus and diphtheria booster vaccinations. Hum. Vaccin. 2, 237-242 (2006).
42. Medicines Control Agency/Committee on Safety of Medicines. Safety of meningococcal group C conjugate vaccines. Curr. Probl. Pharmacovig. 26, 14 (2000).
43. Andrews N, Stowe J, Miller E, Taylor B. Post-licensure safety of the meningococcal group C conjugate vaccine. Hum. Vaccin. 3, 59-63 (2007).
44. Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. Lancet 362, 449-450 (2003).
45. Taylor B, Andrews N, Stowe J, Hamidi-Manesh L, Miller E. No increased risk of relapse after meningococcal C conjugate vaccine in childhood nephrotic syndrome. Arch. Dis. Child. 92, 887-889 (2007).
46. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl. 1), S58-S67 (2001). •• Describes the early impact of the meningococcal serogroup C campaign in the UK.
47. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357, 195-196 (2001).
48. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364, 365-367 (2004). •• Provides the first evidence that booster doses of meningococcal conjugate vaccine are required in the second year of life and highlights the uncertain role of immune memory in protection against disease.
49. Auckland C, Gray S, Borrow R et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the UK. J. Infect. Dis. 194, 1745-1752 (2006).
50. Larrauri A, Cano R, Garcia M, Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23, 4097-4100 (2005).
51. de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J. 25, 79-80 (2006).
52. Arnason S, Thors VS, Gudnason T, Kristinsson KG, Haraldsson A. [Bacteraemia in children in Iceland 1994-2005]. Laeknabladid 94, 523-529 (2008).
53. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359, 1829-1831 (2002). • The first description of the effect of conjugate vaccination on meningococcal serogroup C carriage.
54. Ibarz-Pavon A, Urwin R, Maiden MC. The Meningococcal Carriage Group. Effect of the conjugate serogroup C-polysaccharide vaccine on the carriage and population structure of Neisseria meningitidis. Program and Abstracts of the 8th Meeting of the European Monitoring Group on Meningococci. Dublin, Ireland (2005) (Abstract 7.4).
55. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326, 365-366 (2003).
56. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol. 162, 89-100 (2005). •• Describes a dynamic transmission model that can be utilized for evaluating the impact of different schedules of meningococcal serogroup C vaccination.
57. Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis. 9, 105-110 (1977).
58. De Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24, 3500-3504 (2006).
59. Snape MD, Kelly DF, Lewis S et al. Sero-protection against serogroup C meningococcal is more sustained following immunisation in the second decade of life than the first. BMJ 336, 1487-1491 (2008).
60. Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines www.mhra.gov.uk/home/groups/pl-p/ documents/websiteresources/con2022528.pdf
61. PL CMO (2006) 1: important changes to the childhood immunisation programme www.dh.gov.uk/en/publicationsandstatistics/lettersandcirculars/ professionalletters/chiefmedicalofficerletters/dh-4137171